Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
86.06
USD
|
+1.22%
|
|
-1.40%
|
+20.50%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,832
|
1,599
|
2,581
|
1,128
|
1,245
|
1,546
|
-
|
-
|
Enterprise Value (EV)
1 |
1,832
|
1,599
|
2,581
|
1,128
|
1,245
|
1,546
|
1,546
|
1,546
|
P/E ratio
|
3.27
x
|
-553
x
|
46.2
x
|
-33.7
x
|
24.3
x
|
17.2
x
|
26.7
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.2
x
|
8.58
x
|
9.31
x
|
5.75
x
|
9.48
x
|
11.2
x
|
9.82
x
|
8.05
x
|
EV / Revenue
|
15.2
x
|
8.58
x
|
9.31
x
|
5.75
x
|
9.48
x
|
11.2
x
|
9.82
x
|
8.05
x
|
EV / EBITDA
|
29.3
x
|
20
x
|
15.7
x
|
12.9
x
|
17.7
x
|
16.1
x
|
13.2
x
|
-
|
EV / FCF
|
-57.4
x
|
31.9
x
|
36.9
x
|
9.41
x
|
27
x
|
31
x
|
23.2
x
|
20
x
|
FCF Yield
|
-1.74%
|
3.13%
|
2.71%
|
10.6%
|
3.7%
|
3.23%
|
4.3%
|
5.01%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,563
|
16,081
|
16,712
|
16,894
|
17,436
|
17,964
|
-
|
-
|
Reference price
2 |
104.3
|
99.45
|
154.5
|
66.80
|
71.42
|
86.06
|
86.06
|
86.06
|
Announcement Date
|
2/6/20
|
2/3/21
|
2/17/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
120.3
|
186.4
|
277.1
|
196.2
|
131.3
|
137.9
|
157.5
|
192.1
|
EBITDA
1 |
62.52
|
79.99
|
164.9
|
87.8
|
70.29
|
96.11
|
116.7
|
-
|
EBIT
1 |
-5.721
|
25.84
|
78.9
|
3.037
|
11.94
|
24.76
|
47.75
|
57.63
|
Operating Margin
|
-4.76%
|
13.86%
|
28.47%
|
1.55%
|
9.09%
|
17.95%
|
30.33%
|
30%
|
Earnings before Tax (EBT)
1 |
796.6
|
-10.54
|
47.3
|
36.01
|
63.66
|
121.6
|
65.93
|
-
|
Net income
1 |
629.3
|
-2.985
|
57.59
|
-33.36
|
52.15
|
92.65
|
50.9
|
-
|
Net margin
|
523.19%
|
-1.6%
|
20.78%
|
-17%
|
39.72%
|
67.18%
|
32.32%
|
-
|
EPS
2 |
31.85
|
-0.1800
|
3.340
|
-1.980
|
2.940
|
5.003
|
3.225
|
-
|
Free Cash Flow
1 |
-31.89
|
50.13
|
70.04
|
119.9
|
46.06
|
49.91
|
66.51
|
77.43
|
FCF margin
|
-26.51%
|
26.89%
|
25.27%
|
61.11%
|
35.07%
|
36.19%
|
42.24%
|
40.31%
|
FCF Conversion (EBITDA)
|
-
|
62.67%
|
42.47%
|
136.59%
|
65.52%
|
51.93%
|
57%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
121.62%
|
-
|
88.31%
|
53.87%
|
130.67%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
2/3/21
|
2/17/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
72.47
|
45.69
|
57.42
|
66.09
|
50.38
|
43.98
|
26.37
|
32.87
|
28.1
|
30.98
|
31.97
|
35.31
|
39.65
|
26.94
|
34.36
|
EBITDA
1 |
34.85
|
11.46
|
22.3
|
24.96
|
16.07
|
28.18
|
14.72
|
14.98
|
10.68
|
21.77
|
21.31
|
25.03
|
28.34
|
15.19
|
23.52
|
EBIT
1 |
12.73
|
-9.306
|
-0.469
|
0.636
|
-20.1
|
14.2
|
-1.983
|
-0.122
|
-3.358
|
2.988
|
4.104
|
7.36
|
10.27
|
-1.112
|
7.143
|
Operating Margin
|
17.57%
|
-20.37%
|
-0.82%
|
0.96%
|
-39.89%
|
32.3%
|
-7.52%
|
-0.37%
|
-11.95%
|
9.65%
|
12.84%
|
20.84%
|
25.91%
|
-4.13%
|
20.79%
|
Earnings before Tax (EBT)
1 |
-7.026
|
-20.14
|
-0.636
|
0.857
|
24.14
|
55.54
|
3.171
|
-15.34
|
17.1
|
113.4
|
8.66
|
11.73
|
14.86
|
-0.523
|
7.737
|
Net income
1 |
-4.968
|
-15.38
|
-0.895
|
0.404
|
-17.48
|
41.95
|
2.29
|
-12.79
|
18.19
|
86.14
|
6.682
|
8.974
|
11.43
|
-0.397
|
5.88
|
Net margin
|
-6.85%
|
-33.67%
|
-1.56%
|
0.61%
|
-34.7%
|
95.38%
|
8.69%
|
-38.92%
|
64.72%
|
278.07%
|
20.9%
|
25.41%
|
28.82%
|
-1.47%
|
17.11%
|
EPS
2 |
-0.3000
|
-0.9100
|
-0.0500
|
0.0200
|
-1.040
|
2.330
|
0.1300
|
-0.7400
|
1.030
|
4.750
|
0.4300
|
0.5833
|
0.6767
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/4/22
|
8/8/22
|
11/7/22
|
2/22/23
|
5/4/23
|
8/8/23
|
11/8/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-31.9
|
50.1
|
70
|
120
|
46.1
|
49.9
|
66.5
|
77.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.55
|
4.46
|
8.76
|
17.9
|
3.52
|
5
|
5
|
5.1
|
Capex / Sales
|
2.12%
|
2.39%
|
3.16%
|
9.13%
|
2.68%
|
3.63%
|
3.18%
|
2.66%
|
Announcement Date
|
2/6/20
|
2/3/21
|
2/17/22
|
2/22/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
86.06
USD Average target price
116.8
USD Spread / Average Target +35.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.50% | 1.55B | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|